Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
Vistagen (Nasdaq: VTGN) announced the appointment of Paul Edick to its Board of Directors effective October 29, 2025. Following the appointment the Board will have seven directors.
Mr. Edick will serve on the Audit Committee and the Compensation Committee. He most recently served as Chairman and CEO of Xeris Pharmaceuticals from January 2017 to August 2024 and moved to a senior advisory role after retiring. His prior roles include CEO of Durata Therapeutics (acquired by Actavis) and founding partner of 3G Advisors. Vistagen thanked Dr. Jerry Gin, who served on the Board from 2016 until his retirement in September 2025.
Vistagen (NASDAQ: VTGN) will present poster data on its investigational intranasal pherine PH80 at The Menopause Society 2025 Annual Meeting in Orlando on October 23, 2025. The posters report nonclinical and Phase 1 clinical results exploring PH80’s in vitro receptor binding, effects on reproductive organs in mice, human pharmacokinetics, and impacts on brain and autonomic activity.
PH80 is described as a novel, non-hormonal, non-systemic, rapidly acting pherine nasal spray being evaluated as a potential treatment for vasomotor symptoms (hot flashes) due to menopause. Poster sessions are scheduled for 6:15–7:15 p.m. ET (Poster P-124 and P-13).
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine-based intranasal treatments, announced its participation in the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. CEO Shawn Singh will engage in a fireside chat on September 18, 2025, at 2:20 p.m. ET.
The presentation will be available via live webcast on Vistagen's investor relations website, with a replay option available afterward. The company will also conduct one-on-one meetings during the conference.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company, reported its fiscal Q1 2026 financial results and provided updates on its pherine pipeline. The company's lead program, fasedienol for social anxiety disorder (SAD), is advancing with PALISADE-3 Phase 3 trial results expected in Q4 2025 and PALISADE-4 results in H1 2026.
Financial highlights include R&D expenses of $11.7M (up from $7.6M YoY), G&A expenses of $4.4M, and a net loss of $15.1M. The company maintains a strong cash position of $63.2M as of June 30, 2025.
Vistagen is developing multiple clinical-stage intranasal pherine candidates, including PH80 for menopausal hot flashes and itruvone for major depressive disorder (MDD). The company recently appointed Elissa Cote as Chief Corporate Development Officer.
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has scheduled its fiscal year 2026 first quarter earnings conference call for August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
The company will discuss its financial results for the quarter ended June 30, 2025, and provide updates on its corporate activities. The webcast will be accessible through the Investors section of Vistagen's website and will remain available for at least 90 days after the event.
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Shawn Singh will engage in a fireside chat on Tuesday, July 29, at 10 a.m. Eastern Time.
The company, which specializes in developing intranasal product candidates through nose-to-brain neurocircuitry, will make the fireside chat available via livestream for registered investors, with a recording accessible on the BTIG conference portal afterward. One-on-one meetings with management can be arranged through BTIG representatives.
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has received two significant workplace recognitions in 2025. The company earned the Platinum Bell Seal for Workplace Mental Health from Mental Health America for the third consecutive year, achieving a score between 92-100%. Additionally, Vistagen was certified as a Great Place to Work® for the second consecutive year.
The Platinum Bell Seal recognition places Vistagen among an elite group, as only 40% of assessed employers meet the certification standards. The company's workplace culture evaluation focused on four key areas: workplace culture, benefits, compliance, and wellness programs. According to Great Place to Work® data, certified company employees are 93% more likely to look forward to work and twice as likely to report fair treatment in pay, profit sharing, and promotion opportunities.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company, has appointed Elissa Cote as Chief Corporate Development Officer. With nearly 30 years of experience, Cote will lead strategic opportunities and partnerships for Vistagen's pherine platform, which includes five novel intranasal candidates targeting six prevalent disorders.
Prior to joining Vistagen, Cote served as fractional Chief Business Officer and held senior roles at Mallinckrodt Pharmaceuticals, Sucampo Pharmaceuticals, and MedImmune. As part of her appointment, she received an incentive option to purchase 150,000 shares of Vistagen's common stock, vesting over four years.